Astellas Pharma Inc. - Net Income

Astellas Pharma Inc.'s Fiscal Year is From April To March - All Figures are in JPY, Billions.

The item "Net-Income" stands at 81.57 Billion Japanese Yens for the trailing twelve months (TTM) period ending 06/30/2025, the highest value since 09/30/2023.

Astellas Pharma Inc.'s first quarter result of 68.42 Billion JPY for the item "Net Income" represents a decrease of -8.64 percent compared to it's fourth quarter result of the company's last fiscal year.

Also, Astellas Pharma Inc.'s first quarter result of 68.42 Billion JPY for the item "Net Income" represents an increase of 81.96 percent compared to it's first quarter result of last year.

Looking again at the trailing twelve months series (TTM), Astellas Pharma Inc.'s first quarter result of 81.57 Billion JPY for the item "Net Income" represents an increase of 60.73 percent compared to it's fourth quarter result of the company's last fiscal year.


Regarding the One-Year-Change of the series, the current value constitutes an increase of 64.19 Billion Japanese Yens compared to the value the year prior.
The 1 year change is 64.19 Billion Japanese Yens.
The 3 year change is -36.64 Billion Japanese Yens.
The 5 year change is -105.74 Billion Japanese Yens.
The 10 year change is -63.05 Billion Japanese Yens.

The Serie's long term average value is 127.89 Billion Japanese Yens. It's latest available value, on 06/30/2025, is -46.32 Billion Japanese Yens lower, compared to it's long term average value.
The Serie's change in Japanese Yens from it's minimum value, on 12/31/2024, to it's latest available value, on 06/30/2025, is +138.99 Billion.
The Serie's change in Japanese Yens from it's maximum value, on 09/30/2019, to it's latest available value, on 06/30/2025, is -165.36 Billion.